Lyell Immunopharma (LYEL) closed at $9.41 on October 21, 2026, down 3.0% from the previous close, on volume of 116,973 shares (30-day average 164,944).
Data as of October 21, 2026.
No headlines found.
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
Globe Newswire (Mon, 14-Sep 7:00 AM ET)
Globe Newswire (Thu, 10-Sep 4:05 PM ET)
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma trades on the NASDAQ stock market under the symbol LYEL.
As of October 21, 2026, LYEL stock price declined to $9.41 with 116,973 million shares trading.
LYEL has a beta of 2.23, meaning it tends to be more sensitive to market movements. LYEL has a correlation of 0.10 to the broad based SPY ETF.
LYEL has a market cap of $230.59 million. This is considered a Small Cap stock.
Last quarter Lyell Immunopharma reported $4,000 in Revenue and -$1.92 earnings per share. This fell short of revenue expectation by $-600 and exceeded earnings estimates by $.08.
In the last 3 years, LYEL traded as high as $65.11 and as low as $7.20.
The top ETF exchange traded funds that LYEL belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
LYEL has underperformed the market in the last year with a return of -47.8%, while the SPY ETF gained +16.3%. In the last 3 month period, LYEL fell short of the market, returning -27.2%, while SPY returned +4.4%. However, in the most recent 2 weeks LYEL has outperformed the stock market by returning +9.3%, while SPY returned -0.8%.
LYEL support price is $9.17 and resistance is $10.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYEL shares will trade within this expected range on the day.
